PND29 - Hospital-Based Utilization In Patients With Atypical Hemolytic Uremic Syndrome

Abstract

• Atypical hemolytic uremic syndrome (AHUS) is a rare disease characterized by complement over-activation and represents an estimated 5-10% of all hemolytic uremic syndrome cases.1-2 ‒ Affects approximately 2 per million people in the United States. 3 ‒ Characterized by systemic thrombotic microangiopathy (TMA) which causes blood clots in small vessels throughout the body. These blood clots can lead to stroke, heart attack, kidney failure, and other conditions.2,4-5 • AHUS may be of genetic origin or acquired and shows no variation by race or gender.1 ‒ Although AHUS may develop at any age, it most commonly develops in children under two years of age.6 • Prognosis is poor in patients diagnosed with AHUS with 36-48% of children and 6467% of adults expiring or reaching end stage renal disease (ESRD) within three to five years after onset.5,7 • Treatment for patients with AHUS generally includes plasma exchange or infusion or administration of eculizamab complement inhibitor. HOSPITAL-BASED UTILIZATION IN PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME K. Belk1, C. Craver1,2 1 MedAssets, Inc. 2 University of North Carolina, Charlotte